Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

Prostate Cancer Clinical Trial

Official title:

An Open-Label Study Of Exploratory Pharmacogenomics And Pharmacologic Effects Of Neoadjuvant Oral CCI-779 In Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have A High Risk Of Relapse

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00071968
• Other study ID #: CDR0000331979
• Secondary ID: UCLA-0306091WYET
• Status: Completed
• Phase: Phase 2
• First received: November 4, 2003
• Last updated: January 7, 2013
• Start date: August 2003

Study information

• Verified date: January 2013
• Source: Jonsson Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving CCI-779 before surgery may shrink the tumor so that it can be removed.

PURPOSE: This randomized phase II trial is studying how well CCI-779 works in treating patients who are undergoing radical prostatectomy for newly diagnosed prostate cancer at high risk of relapse.

Description:

OBJECTIVES:

Primary

• Determine the effects of oral CCI-779 on changes in the phosphorylation state of proteins in the mammalian target of rapamycin (mTOR) signaling pathway in the tumor tissue of patients with newly diagnosed prostate cancer undergoing radical prostatectomy.

• Determine the effects of this drug on changes in p70S6 kinase activity, phosphorylation state of mTOR pathway proteins, and on global and targeted gene expression patterns in the peripheral blood mononuclear cells (PBMCs) of these patients.

Secondary

• Determine the effects of this drug on global and targeted gene expression patterns in these patients.

• Identify pharmacodynamic/pharmacogenomic surrogate markers of this drug in both tumor tissue and PBMCs and determine if blood may be used as a surrogate tissue source for biomarkers of drug activity in the tumor in these patients.

• Determine, preliminarily, the potential antitumor effects of this drug in these patients.

• Determine the pharmacokinetics of this drug in these patients.

• Correlate phosphatase and tensin homolog (PTEN) gene status with the pharmacodynamic/pharmacogenomic effects of this drug in these patients.

• Determine the effects of this drug on changes in protein expression patterns in the plasma of these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 3 treatment arms. Patients randomized to arm III are stratified according to tumor expression of phosphatase and tensin homolog (PTEN) gene mutations (negative vs positive).

• Arm I: Patients receive oral CCI-779 once daily for a total of 8 weeks.

• Arm II: Patients receive a higher dose of CCI-779 as in arm I.

• Arm III: Patients receive a higher dose (higher than arm II) of CCI-779 as in arm I.

Approximately 24-48 hours after the last dose of CCI-779, patients in all arms undergo radical prostatectomy.

Patients are followed on day 7-10 and then at 4 weeks after study completion.

PROJECTED ACCRUAL: A total of 40 patients (5 each for arms I and II and 30 for arm III) will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. primary completion date: May 2006
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the prostate

• Diagnosis based on a minimum of 6 core biopsy samples

• Clinically confirmed organ-confined disease

• Candidate for radical prostatectomy

• No evidence of metastatic disease by CT scan and bone scan

• High risk of relapse based on either of the following criteria:

• Any one of the following:

• Stage T2C or higher

• Gleason score greater than 7

• Prostate-specific antigen (PSA) greater than 20 ng/mL OR

• Any two of the following:

• Gleason score at least 7

• PSA 10-20 ng/mL

• Greater than 50% of total biopsy cores with cancer involvement

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-1

Life expectancy

• Not specified

Hematopoietic

• No active bleeding

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 10 g/dL

Hepatic

• No acute or chronic hepatitis B

• Hepatitis B surface antigen negative

• No acute or chronic hepatitis C

• No antibodies to hepatitis C

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• AST and ALT no greater than 2 times ULN

Renal

• No ongoing urinary tract infection necessitating rapid or emergent surgical resection

• Creatinine no greater than 1.5 times ULN

Cardiovascular

• No unstable angina

• No myocardial infarction within the past 6 months

• No life-threatening ventricular arrhythmia requiring ongoing maintenance therapy

Pulmonary

• No known pulmonary hypertension

• No pneumonitis

Other

• Fertile patients must use effective contraception during and for 12 weeks after study participation

• HIV negative

• No other severe immunocompromised states

• No active infection requiring antibiotic therapy

• No serious concurrent illness

• No other major illness that would substantially increase the risk associated with study participation

• No other malignancy within the past 5 years except basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No concurrent immunotherapy

Chemotherapy

• No prior chemotherapy

• No other concurrent chemotherapy

Endocrine therapy

• More than 3 weeks since prior IV corticosteroids

• No concurrent systemic corticosteroids

• No prior or concurrent hormonal therapy for underlying malignancy

Radiotherapy

• No prior or concurrent radiotherapy

Surgery

• More than 3 months since prior major surgery

Other

• More than 1 month since prior experimental drugs

• More than 3 weeks since prior immunosuppressive agents

• No concurrent immunosuppressive therapies

• No other concurrent investigational agents

• No concurrent enzyme-inducing anticonvulsants (e.g., phenobarbital, phenytoin, or carbamazepine)

• No concurrent ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole, pimozide, or Hypericum perforatum (St. John's wort)

• No concurrent grapefruit or grapefruit juice

Study Design

Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• temsirolimus

Procedure:
• conventional surgery

• neoadjuvant therapy

Locations

Country	Name	City	State
United States	Jonsson Comprehensive Cancer Center at UCLA	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Jonsson Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Thomas G, Speicher L, Reiter R, et al.: Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. [Abstract] Clin Cancer Res 11 (Suppl 24): A-C131, 2005.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phosphorylation state of proteins			No
Primary	p70S6 kinase activity			No
Primary	Phosphorylation state of mTOR pathway proteins			No
Primary	Global and targeted gene expression patterns in peripheral blood mononuclear cells			No
Secondary	Global and targeted gene expression patterns			No
Secondary	Pharmacodynamics and pharmacogenomic surrogate markers			No
Secondary	Antitumor effects			No
Secondary	Pharmacokinetics			No
Secondary	Correlation of phosphatase and tensin homolog gene status with pharmacodynamic and pharmacogenomic effects			No
Secondary	Protein expression patterns in the plasma			No